AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 274: R1078-R1086, 1998;
0363-6119/98 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, C.
Right arrow Articles by Liu, M.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, C.
Right arrow Articles by Liu, M.-S.
Vol. 274, Issue 4, R1078-R1086, April 1998

Phosphorylation of beta -adrenergic receptor leads to its redistribution in rat heart during sepsis

Chaoshu Tang, Jung Yang, Li-Ling Wu, Lin-Wang Dong, and Maw-Shung Liu

Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, Saint Louis, Missouri 63104

    ABSTRACT
Top
Abstract
Introduction
Methods
Results
Discussion
References

The role of receptor phosphorylation on the redistribution of beta -adrenergic receptors (beta -ARs) in rat hearts during different phases of sepsis was investigated. Sepsis was induced by cecal ligation and puncture (CLP). Changes in the distribution of beta -ARs in the sarcolemmal and light vesicle fractions were studied using (-)-[4,6-propyl-3H]dihydroalprenolol ([3H]DHA). Phosphorylation of beta -ARs was studied by perfusing hearts with [32P]H3PO4 followed by identification of the phosphorylated beta -ARs with immunoprecipitation using anti-beta 1-AR antibody. The results show that septic rat hearts exhibit an initial hypercardiodynamic (9 h after CLP; early sepsis) and a subsequent hypocardiodynamic (18 h after CLP; late sepsis) state. [3H]DHA binding studies show that, during early sepsis, the maximum binding capacity (Bmax) was increased by 26% in sarcolemma but was decreased by 30% in light vesicles, whereas, during late sepsis, the Bmax was decreased by 39% in sarcolemma but increased by 31% in light vesicles. These data indicate that beta -ARs in the rat heart were externalized from light vesicles to sarcolemma during early sepsis but were internalized from surface membranes to intracellular sites during late sepsis. The immunoprecipitation studies reveal that the externalization of beta -ARs during early sepsis was coupled with a concomitant decrease (-28.5 to -30.6%, P < 0.01) in the receptor phosphorylation, whereas the internalization of beta -ARs during late sepsis was accompanied by a simultaneous increase (30.3 to 33.8%, P < 0.01) in the receptor phosphorylation. Because the phosphorylation/dephosphorylation of beta 1-ARs regulate their functional coupling and may reflect their subcellular distribution, it is suggested that the increase in receptor phosphorylation seen in late sepsis leads to the receptor internalization observed in late sepsis; similarly, externalization of (dephosphorylated) receptors in early sepsis may give rise to the apparent decrease in sarcolemmal receptor phosphorylation observed during this interval.

receptor externalization (overexpression); receptor internalization (underexpression); sarcolemmal membrane; light vesicle; septic shock

    INTRODUCTION
Top
Abstract
Introduction
Methods
Results
Discussion
References

beta -ADRENERGIC RECEPTORS (beta -ARs) play an important role in the mediation of adrenergic control of cardiac muscle contraction. Any alterations in the dynamics of these receptors would affect myocardial function as a pump. Studies on the regulation of adrenergic receptors have indicated that beta -ARs are in a dynamic life cycle involving receptor appearance on, and disappearance from, the cell surface (7, 14, 15). Under physiological conditions, cardiac beta -ARs are distributed in the sarcolemmal membranes and the light vesicles, a distinct cytosolic compartment that is deficient in Gs protein (14, 17). Under certain pathological conditions, however, the distribution of beta -ARs in the heart can be altered either by internalization from surface membranes to light vesicles or by externalization from intracellular sites to sarcolemmal membranes (4, 9, 14, 15, 17, 26, 30). In septic shock, we have reported earlier that beta -ARs in the rat heart undergo an externalization from light vesicles to sarcolemma during the early phase of sepsis, whereas they are internalized from surface membranes to intracellular sites during the late phase of sepsis (28). Because myocardial contractility is regulated by catecholamines through beta -AR mediation, an externalization (overexpression) of beta -ARs during the initial phase of sepsis is most likely to contribute to the development of the hypercardiodynamic state, whereas an internalization (underexpression) of beta -ARs during the late phase of sepsis would lead to the formation of hypocardiodynamic state (28). Because phosphorylation/dephosphorylation of receptors has been considered to represent a common mechanism through which recycling of receptors can be regulated (7, 12, 14, 24, 25), the present study dealing with the role of receptor phosphorylation on the biphasic redistribution of beta -ARs in the rat heart during different phases of sepsis was undertaken in an attempt to uncover the pathogenesis of sepsis-induced alterations in cardiac function.

    METHODS
Top
Abstract
Introduction
Methods
Results
Discussion
References

Animal model. Male Sprague-Dawley rats weighing from 270 to 320 g were used. All animals were fasted overnight with free access to water. They were divided into three groups: control, early sepsis, and late sepsis. Sepsis was induced by cecal ligation and puncture (CLP) as described by Wichterman et al. (31) with minor modification. With the rats under halothane anesthesia, a laparotomy was performed (the size of the incision was ~2.5 cm), and the cecum was ligated with a 3-0 silk ligature and punctured twice with an 18-gauge needle. The cecum was then returned to the peritoneal cavity and the abdomen was closed in two layers. Control rats were sham operated (a laparotomy was performed and the cecum was manipulated, but neither ligated nor punctured). All animals were resuscitated with 4 ml/100 g body wt normal saline at the completion of surgery and also at 7 h postsurgery. Animals were fasted, but had free access to water after operative procedures. Hearts were removed from septic and control animals 9 or 18 h postoperation under chloralose and urethan anesthesia and were then subjected to perfusion as described below. Early and late sepsis refers to those animals killed at 9 and 18 h, respectively, after CLP. The mortality rates were 0% (0/20) for control, 15.4% (4/26) for early sepsis, and 36.4% (12/33) for late sepsis.

Phosphorylation of beta -ARs. Studies of the phosphorylation of beta -ARs involved labeling of the tissue ATP pool by perfusion of isolated intact hearts with inorganic [32P]phosphate, isolation of sarcolemmal membranes and light vesicles by homogenization and centrifugation, and quantification of 32P-labeled beta -ARs by immunoprecipitation with anti-beta 1-AR antibody or antiserum. Hearts removed from control or septic rats were retrogradely perfused (nonrecirculating) by the Langendorff technique under constant pressure (70-80 cmH2O) at 37°C with Krebs-Henseleit (KH) buffer (in mM: 118.4 NaCl, 4.7 KCl, 1.2 MgCl2, 2.5 CaCl2, 10 glucose, 25 NaHCO3, and 0.1 KH2PO4/K2HPO4; pH 7.3) for 5 min (first perfusion) followed by a 25-min perfusion (recirculating) with KH buffer in the presence of [32P]H3PO4 (2 mCi/50 ml) to label the tissue ATP pool (second perfusion). At the end of the second perfusion, the hearts were perfused (nonrecirculating) for 5 min with KH buffer in the absence of [32P]H3PO4 to wash out radioactivity (third perfusion). In some experiments, 3 × 10-8 M of isoproterenol was present during the third perfusion. It should be noted that an isoproternol concentration >3 × 10-8 M caused perfused myocardium to contract. All of the perfusion solutions were gassed continuously with 95% O2-5% CO2 throughout the entire perfusion period. At the end of the third perfusion, heart ventricles were rapidly frozen by freeze-clamping with aluminum clamps precooled in liquid nitrogen and then pulverized. The pulverized myocardium was then used for the following: isolation and purification of sarcolemmal and light vesicle fractions, determination of ATP concentration, and examination of the phosphorylated beta -ARs by immunoprecipitation. The isolation and purification of cardiac sarcolemma and light vesicles were carried out by a procedure involving a series of repeated homogenization, centrifugation, and sucrose gradient separation as described previously (28). Myocardial ATP was extracted by the method of CoGoli and Dobson (5), and its content was quantified by the method of Adams (1). The phosphorylated beta -ARs were separated and analyzed by SDS-PAGE (7.5-9.5% acrylamide gradient gel) (28).

Determination of the molecular weight of the phosphorylated beta -ARs. The molecular weight of the phosphorylated beta -ARs was determined by photoaffinity labeling of cardiac membranes with [125I]iodocyanopindolol ([125I]ICYP) in the presence of ATP and the catalytic subunit of the cAMP-dependent protein kinase followed by SDS-PAGE and autoradiography (28). The experiments were conducted as described previously (28) except that 1) sarcolemmal membranes and light vesicles were prepared from hearts perfused in the absence of [32P]H3PO4 and 2) the reaction mixture contained 100 mM KCl, 3 mM MgCl2, 20 mM NaF, 50 mM histidine, pH 7.4, in the absence or presence of ATP (0.2 mM) plus the catalytic subunit of the cAMP-dependent protein kinase (50 U/ml).

Immunoprecipitation of the phosphorylated beta -ARs. Immunoprecipitation of the phosphorylated beta -ARs was performed as described by Bahouth et al. (2) and Jahns et al. (8) with modifications. Cardiac sarcolemmal membranes and light vesicles prepared from hearts perfused in the presence of [32P]H3PO4 were solubilized with 1% 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS) and 0.25% Triton X-100 in buffer A (300 mM NaCl, 0.15 mM CaCl2, 0.1 mM EGTA, 25 mM NaF, 0.1 mM phenylmethylsulfonyl fluoride, 1 µg/ml soybean trypsin inhibitor, 1 µg/ml aprotinin, 0.75 µg/ml pepstatin A, 2 µg/ml leupeptin, and 25 mM HEPES-Tris, pH 7.4) for 40 min on ice. The solubilisates were diluted 1:1 with buffer A containing 0 NaCl, followed by centrifugation at 104,000 g for 30 min. The resulting supernatants were incubated with 1:50 dilution of anti-beta 1-AR antiserum SB-03 prepared against a peptide corresponding to amino acids 396-408 in rat beta 1-AR (the antiserum SB-03 was a generous gift from Dr. S. W. Bahouth) or 1:200 dilution of polyclonal anti-beta 1-AR antibody (Affinity Bioreagents) at 4°C for 14 h in a rotating platform. Rabbit serum and rabbit IgG were used as antibody control for anti-beta 1-AR antiserum SB-03 and polyclonal anti-beta 1-AR antibody, respectively. Subsequently, 60 µl of rabbit serum-agarose or rabbit IgG-agarose, preblocked with 2% nonfat dry milk in buffer B (buffer A containing 0.1% CHAPS and 0.025% Triton X-100), was added and incubated for 2 h at 4°C. Finally, the resin was washed four times with buffer B and once more with buffer A. The immunoprecipitated proteins were then analyzed by SDS-PAGE. The phosphorylated beta 1-AR signals were scanned and quantified with PhosphoImager and ImageQuant (Molecular Dynamics).

Assays of beta -ARs. Assay of beta -ARs was performed using (-)-[4,6-propyl-3H]dihydroalprenolol ([3H]DHA) as a radioligand as described previously (28), except that sarcolemmal membranes and light vesicles were isolated from hearts perfused in the same manner but in the absence of [32P]H3PO4 for the studies of the phosphorylation of beta -ARs.

Measurements of the physiological parameters of perfused rat hearts. Physiological parameters such as heart rate, maximum change in pressure over change in time (±dP/dtmax), and left ventricular developed pressure (LVDP) (left ventricle end-systolic pressure minus left ventricle end-diastolic pressure) of perfused rat hearts were measured with a polygraph. A latex balloon catheter filled with saline was inserted into the left ventricle via the left atrium to measure left ventricular pressure. The volume of the balloon was adjusted to produce a left ventricular end-diastolic pressure of 6 mmHg at baseline condition. The catheter was connected to a pressure transducer (Statham P23 Db), and the heart rate, the ±dP/dtmax, and the LVDP were recorded on a polygraph (Grass Instruments, model 79D) equipped with a direct differentiator.

Other measurements. Membrane marker enzyme activities were determined as previously described (28). The protein content of cardiac membranes was determined by the method of Lowry et al. (13). For measurement of heart cAMP content, 100 mg of frozen tissue sample from nonradioactive perfused hearts were homogenized at 4°C in a buffer containing 50 mM Tris · HCl, pH 7.5, and 4 mM EGTA. The homogenates were heated for 10 min in a boiling water bath. After centrifugation, the cAMP in the supernatant was assayed by the method of Tovey et al. (29).

Statistical analysis. The statistical analysis of the data was performed using one-way ANOVA followed by multiple comparison procedures. Statistical significance was accepted at the 95% confidence limit.

Materials. [3H]DHA (90 Ci/mmol) and [125]ICYP (2,000 Ci/mmol) were purchased from Amersham and DuPont-NEN, respectively. (-)-Alprenolol, (-)-isoproterenol, 5'-guanylyl imidodiphosphate [Gpp(NH)p], the catalytic subunit of the cAMP-dependent protein kinase, soybean trypsin inhibitor, aprotinin, pepstatin A, leupeptin, SDS, and EGTA were products of Sigma Chemical. Polyclonal anti-beta 1-AR antibody was obtained from Affinity Bioreagents. Anti-beta 1-AR antiserum SB-03 was a generous gift from S. W. Bahouth, The University of Tennessee, Memphis. Other chemicals and reagents were of analytic grade.

    RESULTS
Top
Abstract
Introduction
Methods
Results
Discussion
References

Table 1 shows the effects of perfusion on marker enzyme activities and protein yield of various membrane preparations and on myocardial dry-to-wet weight ratio and ATP content of control animals. Na+-K+-ATPase serves as marker for sarcolemmal membrane, whereas glucose-6-phosphatase serves as marker for sarcoplasmic reticulum. Na+-K+-ATPase activities were enriched by 28- and 6-fold for sarcolemmal and light vesicle fractions, respectively, in nonperfused hearts. The pattern of enrichment in the activities of Na+-K+-ATPase in the sarcolemmal and light vesicle fractions of perfused hearts was essentially identical to that of nonperfused hearts. Glucose-6-phosphate activities were the same in nonperfused and perfused hearts, and, furthermore, the activities were not enriched in sarcolemmal and light vesicle fractions in either nonperfused or the perfused hearts. The yield of protein for each specific membrane preparation was virtually identical in nonperfused and perfused hearts. The dry-to-wet wt ratio of the myocardium was also constant between nonperfused and perfused hearts. Myocardial ATP content remained unaltered after perfusion (Table 1). It should be mentioned that, for septic animals, the pattern of enrichment in the activities of the enzymatic markers in each subcellular fraction, the protein yield, the dry-to-wet wt ratio, and the ATP content of the myocardium were essentially identical between the perfused and nonperfused hearts (results not shown). These data indicate that sarcolemmal and light vesicle fractions were highly purified, and, furthermore, the integrity of membrane preparations and the metabolic status of the myocardium were unaffected by the perfusion procedure for the control as well as for the septic animals.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Effects of perfusion on marker enzyme activities, protein yield, and dry-to-wet weight ratio of various membrane preparations and on myocardial ATP content of control animals

Figure 1 depicts changes in the electrophoretic mobility of beta -ARs phosphorylated by the catalytic subunit of the cAMP-dependent protein kinase in cardiac membranes isolated from control animals. In the absence of ATP and the catalytic subunit of the cAMP-dependent protein kinase, one single-binding peptide with a molecular mass of 64,000 Da was labeled with [125I]ICYP and visualized in both the light vesicle and sarcolemmal fractions (Fig. 1, lanes 1 and 4). The electrophoretic mobility of the 125I-labeled 64,000-Da peptides were shifted to 68,000 Da in both membrane fractions when ATP and the catalytic subunit of the cAMP-dependent protein kinase were present in the reaction mixture (Fig. 1, lanes 2 and 5). The labeling of 68,000-Da peptides in the presence of ATP and the catalytic subunit of the cAMP-dependent protein kinase were completely inhibited by a specific beta -AR antagonist, alprenolol (Fig. 1, lanes 3 and 6), indicating that the 68,000-Da peptides possess beta -AR specificity. These data indicate that the electrophoretic mobility of beta -ARs was shifted from 64,000 to 68,000 Da on phosphorylation of the receptors by cAMP-dependent protein kinase. It should be mentioned that, for septic animals, similar shift in the molecular weight was also observed on the phosphorylation of beta -ARs (results not shown). The 68,000 Da was then used for the identification of the molecular mass for the phosphorylated beta -ARs in the experiments perfused with [32P]H3PO4 (Figs. 2-4).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 1.   Representative experiment of the autoradiography from SDS-PAGE of beta -adrenergic receptors (beta -AR) labeled with [125I]iodocyanopindolol ([125I]ICYP) in cardiac sarcolemma and light vesicles of control rats. Membranes were reacted with [125I]ICYP in the presence (+) or absence (-) of alprenolol (10 µM), ATP (0.2 mM), or the catalytic subunit of the cAMP-dependent protein kinase (50 U/ml). Numbers at left represent position of molecular mass standards in kDa.

Figures 2 and 3 show immunoprecipitation of the phosphorylated beta -ARs by specific antiserum/antibody raised against beta 1-AR in the sarcolemmal (Fig. 2) and light vesicle (Fig. 3) fractions from control and septic rat hearts after perfusion with [32P]H3PO4. Figure 4 summarizes quantitative results obtained from immunoprecipitation analysis. The phosphorylated beta 1-AR (68,000 Da) from immunoprecipitation (Figs. 2 and 3, lanes 2, 4, and 6) comigrates with beta 1-AR from Western blotting (Figs 2 and 3, lane 7). No signals from immunoprecipitation were detected in the bands corresponding to 68,000 Da when specific antiserum/antibody was substituted by antibody control (rabbit IgG) (Figs. 2 and 3, lanes 1, 3, and 5). Analysis of the signals by PhosphoImager and ImageQuant (Fig. 4) indicates that, in sarcolemma membrane, the extent of beta 1-AR phosphorylation was decreased by 28.5% (P < 0.01) during early phase, whereas it was increased by 33.8% (P < 0.01) during late phase of sepsis (in arbitrary units: 100, 71.5 ± 1.7, and 133.8 ± 2.3 for control, early sepsis, and late sepsis, respectively; n = 4) (Fig. 4A). In light vesicle fraction, the extent of beta 1-AR phosphorylation was decreased by 30.6% (P < 0.01) during early sepsis, but it was increased by 30.3% (P < 0.01) during late sepsis (in arbitrary units: 100, 69.4 ± 2.3, and 130.3 ± 4.1 for control, early sepsis, and late sepsis, respectively; n = 4) (Fig. 4B). These results unequivocally demonstrate that the phosphorylation of beta -ARs in cardiac sarcolemma and light vesicles was decreased during early sepsis, whereas it was increased during late sepsis.


View larger version (75K):
[in this window]
[in a new window]
 
Fig. 2.   Immunoprecipitation of the phosphorylated beta 1-AR in rat heart sarcolemma. Immunoprecipitation of the phosphorylated beta 1-AR was conducted as described in METHODS (lanes 1-6). Experiments were conducted in the presence (+) of polyclonal anti-beta 1AR antibody containing 1.76 µg protein or in the presence (-) of rabbit IgG containing 4.6 µg protein as antibody control. Position of the phosphorylated beta 1-AR from immunoprecipitation comigrates with beta 1-AR from Western blotting (lane 7). For Western blotting, lane 7 (control rat) was run simultaneously with lanes 1-6 on SDS-PAGE, excised, and transferred to polyvinylidene fluoride membrane and analyzed by Western blotting using identical antibody as for immunoprecipitation. Numbers at left represent position of mass standards. ES, early sepsis. LS, late sepsis.


View larger version (87K):
[in this window]
[in a new window]
 
Fig. 3.   Immunoprecipitation of the phosphorylated beta 1-AR in rat heart light vesicles. Experiments were conducted as described in Fig. 2, except that light vesicle, instead of sarcolemma, was used. Numbers at left represent position of mass standards.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   Changes in the phosphorylation of beta -ARs in the sarcolemmal (A) and light vesicle (B) fractions of rat hearts during different phases of sepsis. Experimental conditions were identical to those for Figs. 2 and 3. Vertical bars indicate standard errors of the mean. Number of experiments for each specific group indicated in parentheses. ** P < 0.01.

Figure 5 depicts changes in the dynamics of beta -ARs in rat heart sarcolemmal and light vesicle fractions during different stages of sepsis based on [3H]DHA binding studies. In sarcolemmal membrane fraction (Fig. 5A), the maximal binding capacity (Bmax; calculated from Scatchard plots) (Scatchard plots not shown) for [3H]DHA binding was increased by 26% (P < 0.05) during early sepsis but was decreased by 39% (P < 0.01) during late sepsis (135.7 ± 3.7, 171.1 ± 2.8, and 83.0 ± 7.4 fmol/mg for control, early sepsis, and late sepsis, respectively). In light vesicle fraction (Fig. 5B), the Bmax for [3H]DHA binding was decreased by 30% (P < 0.01) during early sepsis, but was increased by 31% (P < 0.01) during late sepsis (91.1 ± 2.9, 63.6 ± 1.3, and 119.4 ± 3.5 fmol/mg for control, early sepsis, and late sepsis, respectively). The dissociation constant values were unaffected during early and late sepsis in both membrane fractions (sarcolemma: 3.5 ± 0.2, 3.1 ± 0.2, and 3.6 ± 0.1 nM for control, early sepsis, and late sepsis, respectively; light vesicle: 3.3 ± 0.1, 3.3 ± 0.2, and 3.6 ± 0.1 nM for control, early sepsis, and late sepsis, respectively). It should be mentioned that the binding of [3H]DHA in the sarcolemma was inhibited significantly by isoproterenol perfusion in the control, the early-sepsis, and the late-sepsis experiments (Fig. 5A). In contrast, isoproterenol perfusion stimulated significantly the [3H]DHA binding in light vesicles in the control and early-sepsis experiments (Fig. 5B). Because the Bmax for [3H]DHA binding was increased in the sarcolemma but was decreased in the light vesicles during early sepsis, and, conversely, the Bmax was decreased in the sarcolemma but was increased in the light vesicles during late sepsis, it is concluded that beta -ARs in the rat heart were externalized from light vesicles to sarcolemmal membranes (hyperexpression) during early sepsis but were internalized from surface membranes to intracellular sites (hypoexpression) during late sepsis.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   Changes in the density of beta -AR in the sarcolemmal (A) and light vesicle (B) fractions of rat hearts during different phases of sepsis. beta -AR were assayed as described in METHODS using [3H]dihydroalprenolol ([3H]DHA) as a radioligand. Hearts were perfused in the presence (+) or absence (-) of isoproterenol (3 × 10-8 M) during the third perfusion period. Vertical bars indicate standard errors of the mean. * P < 0.05; ** P < 0.01; NS, not significant.

Table 2 shows the modulation of beta -ARs by guanine nucleotide Gpp(NH)p in sarcolemmal and light vesicle fractions prepared from control and septic rat hearts. In sarcolemmal membranes prepared from control rats, addition of Gpp(NH)p caused a rightward shift in the isoproterenol competition curve, with an increase in IC50 (concentration of unlabeled ligand required to inhibit 50% of the binding of labeled ligand) value from 7 × 10-7 to 9 × 10-6 M. These data indicate that, in sarcolemmal membranes prepared from control rat hearts, agonists recognize two classes of beta -ARs: a high-affinity class of receptors coupled to guanine nucleotide binding stimulation protein (Gs) and a low-affinity class of receptors apparently uncoupled from Gs. In contrast, the competitive binding studies for isopreterenol in the light vesicles prepared from control rat hearts demonstrate only low-affinity binding of isoproterenol with an IC50 value of 5 × 10-6 M, and this binding was not affected by Gpp(NH)p. These findings indicate that the light vesicles are functionally and presumably physically uncoupled from Gs, consistent with the notion that light vesicles are the intracellular sites of surface receptors (7, 14). During early sepsis, addition of Gpp(NH)p shifted the agonist competition curve to the right, with an increase in IC50 value from 6 × 10-7 to 6 × 10-6 M in the sarcolemmal membranes, but it failed to affect the IC50 value of the light vesicles. It should be noted that the IC50 values reported in the literature vary considerably; some investigators reported comparable (3, 22), whereas others reported higher (6, 10) or lower (18, 23), values. These data support the findings presented in Fig. 5 that beta -ARs are externalized from light vesicles to sarcolemma in rat heart during the early phase of sepsis. During late sepsis, addition of Gpp(NH)p failed to modulate the IC50 values in sarcolemmal and light vesicle fractions because of receptor uncoupling consequent to hyperphosphorylation, which can be seen in the data presented in Figs. 4 and 5.

                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Modulation of beta -adrenergic receptors by Gpp(NH)p in SL and LV fractions prepared from control and septic rat hearts

Figure 6 illustrates the relationship between changes in the intracellular redistribution of beta -ARs and alterations in the receptor phosphorylation in rat hearts during different phases of sepsis. In the sarcolemmal fraction, the number of beta -ARs increases (externalization) during the early phase of sepsis (9 h after CLP) coupled with a simultaneous decrease in the receptor phosphorylation, whereas the number of beta -ARs decreases (internalization) during late sepsis (18 h after CLP) accompanied with a concurrent increase in the receptor phosphorylation (Fig. 6A). In light vesicle fraction, the decrease in the number of beta -ARs (externalization) during early sepsis coincided with a decrease in the receptor phosphorylation, whereas the increase in the number of beta -AR (internalization) during late sepsis correlated with a concomitant increase in the receptor phosphorylation (Fig. 6B). Because phosphorylation/dephosphorylation has been considered to be a common mechanism through which recycling of receptors can be regulated (7, 12, 14, 24, 25), our data presented in Fig. 6 strongly suggest that a decrease in the receptor phosphorylation is a mechanism for externalization of beta -ARs during early sepsis, whereas an increase in the receptor phosphorylation is a mechanism for internalization of beta -ARs during late sepsis.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6.   Relationship between changes in the intracellular redistribution of beta -AR and alterations in the receptor phosphorylation in rat hearts (A, sarcolemma; B, light vesicles) during different phases of sepsis. Figures were constructed using data presented in Figs. 4 and 5 in which hearts were perfused in the absence of isopreterenol during the third perfusion period. CLP, cecal ligation and puncture. Vertical bars indicate SE. * P < 0.05; ** P < 0.01 compared with zero time in each specific group.

Table 3 illustrates the baseline and isoproterenol-stimulated physiological parameters in perfused hearts isolated from control and septic rats. Baseline heart rates remained unaltered for all three experimental groups, but they were stimulated by isoproterenol within each respective group. Left ventricle +dP/dtmax was increased by 19.5% (P < 0.01) in early sepsis but was decreased by 39.7% (P < 0.01) during late sepsis under basal conditions, indicating that myocardial basal contractility was enhanced during early sepsis but diminished during late sepsis. Isoproterenol increased basal left ventricle +dP/dtmax in control, early sepsis, and late sepsis, indicating that myocardial basal contractility was enhanced in all three experimental groups, and, furthermore, the enhancement of basal contractility induced during the early stage of sepsis had not reached maximum. Basal left ventricle -dP/dtmax was unaffected during early sepsis but it was decreased by 48.3% (P < 0.01) during late sepsis, indicating that myocardial basal relaxation remained unimpaired during early sepsis but was diminished during late sepsis. Isoproterenol, as expected, stimulated basal relaxation in all three experimental groups. These alterations in the parameters of contraction and relaxation were associated with a moderate, but nonsignificant, increase (13.5%; 0.05 < P < 0.1) in LVDP during early sepsis followed by a significant decrease (-48.3%; P < 0.05) in LVDP during late sepsis. The basal LVDP was responsive to isoproterenolol stimulation in all three experimental groups. The basal tissue cAMP contents show a biphasic change during the course of sepsis: an increase in early sepsis (26.5%; P < 0.01) followed by a decrease in late sepsis (-30.6%; P < 0.01). The basal tissue cAMP contents were stimulated as expected by isoproterenol. The observed changes in the physiological parameters described above illustrate that during early sepsis myocardium is in the hyperdynamic state, whereas during late sepsis myocardium is in the hypodynamic state.

                              
View this table:
[in this window]
[in a new window]
 
Table 3.   Baseline and isoproterenol-stimulated physiological parameters in perfused hearts isolated from control and septic rats

    DISCUSSION
Top
Abstract
Introduction
Methods
Results
Discussion
References

In this study we used isolated intact hearts perfused with [32P]H3PO4 to label the cellular ATP pool followed by isolation and purification of sarcolemmal and light vesicle membrane fractions. The phosphorylation status of the membrane receptors was then examined by immunoprecipitation with anti-beta 1-AR antiserum/antibody. This approach in monitoring phosphorylation of beta -ARs has traditionally been of great use in establishing the functional relevance and the significance of receptor phosphorylation (2, 8, 19). During the course of our study, great care was taken to assure that various physiological and biochemical parameters such as energetic state of the myocardium and the purity and integrity of sarcolemmal and light vesicle preparations were not compromised by the perfusion procedure. This was evident by data presented in Table 1 demonstrating that ATP content and the dry-to-wet wt ratio of the myocardium and the marker enzyme activities of various membrane fractions remained unaffected after completion of perfusion. In examining the phosphorylation status of beta -ARs by PAGE, the shift in the receptor electrophoretic mobility was verified by the in vitro phosphorylation in the presence of exogenous cAMP-dependent protein kinase (Fig. 1). This shift in the receptor mobility on phosphorylation is consistent with findings reported in the literature (12, 24).

After establishing that the metabolic state of the myocardium and the integrity of subcellular membranes remained unaffected by perfusion procedure and after clarifying the shift in the electrophoretic mobility of beta -ARs on phosphorylation, we then examined the receptor binding characteristics and the incorporation of [32P]ATP into beta -ARs. Binding assays using [3H]DHA as a radioligand demonstrate that, in sarcolemmal membrane fraction, the Bmax was increased by 26% during early sepsis but was decreased by 39% during late sepsis. In light vesicle fraction, the Bmax for [3H]DHA binding was decreased by 30% during early sepsis but was increased by 31% during late sepsis (Fig. 5). These data indicate that beta -ARs were externalized from light vesicles to sarcolemmal membranes during early sepsis, whereas they were internalized from surface membranes to intracellular sites during late sepsis. The biphasic redistribution of beta -ARs between the two different intracellular compartments during the progression of sepsis was further verified by Gpp(NH)p modulation studies (Table 2). Gpp(NH)p caused a rightward shift with an increase in the IC50 value in the sarcolemmal membranes of control and early septic rats, whereas it failed to affect the agonist-binding displacement curves in the sarcolemmal membranes of late septic rats as well as the light vesicle fractions of all experimental groups (control, early, and late sepsis) (Table 2). These data are in agreement with the notion that during early sepsis beta -ARs were externalized to the surface membranes where agonists recognized two classes of beta -ARs, a high-affinity class of receptors (IC50 = 6 × 10-7 M) coupled to Gs and a low-affinity class of receptors (IC50 = 6 × 10-6 M) apparently uncoupled to Gs protein, whereas during late sepsis the beta -ARs were internalized to intracellular sites where agonists recognized only the low-affinity class of receptor (IC50 = 1 × 10-6 M) and were deficient in Gs protein (7, 14). It should be pointed out that the results obtained using perfused hearts in regard to changes in the intracellular distribution of beta -ARs, as reported in this study, were identical to those reported earlier using nonperfused hearts (28). Further investigation on the immunoprecipitation of the phosphorylated beta 1-ARs using hearts perfused with [32P]H3PO4 reveals that the incorporation of [32P]ATP into beta -ARs in both the sarcolemmal and light vesicles were decreased by 28.5-30.6% (P < 0.01) during early sepsis but was increased by 30.3-33.8% (P < 0.01) during late sepsis (Figs. 2-4). These results, together with those of binding studies (Fig. 5), unequivocally demonstrate that the externalization of beta -ARs during early sepsis was coupled with a concomitant decrease in the receptor phosphorylation, whereas the internalization of beta -ARs during late sepsis was accompanied by a simultaneous increase in the receptor phosphorylation (Fig. 6).

beta -AR consists of two major subtypes, beta 1 and beta 2, with beta 1 being the predominant subtype (~90%) expressed in mammalian heart (27). In our study, the phosphorylated beta -ARs were identified by the molecular weight corresponding to beta 1-AR (Fig. 1) and further verified by immunoprecipitation with specific antiserum/antibody raised against beta 1-AR (Figs. 2 and 3). The receptor binding assay was conducted using cold alprenolol, a beta 1-selective antagonist (20), to displace [3H]DHA binding (Fig. 5). These data indicate that the beta -AR we studied represents beta 1-AR.

The pathophysiological significance between changes in the intracellular distribution of beta -ARs and alterations in the phosphorylation of receptors during different phases of sepsis, as reported in this study, is apparent. Progress in the studies of the regulation of beta -AR function indicates that increased phosphorylation of beta -AR leads to its functional uncoupling and physical translocation away from the cell surface into a sequestered compartment, and, once the receptors are sequestered, the phosphorylation is reversed, perhaps enabling the receptors to translocate back to the cell surface (7, 12, 14, 24, 25). Because the externalization of beta -ARs during early sepsis coincides with the reduced state of phosphorylation, whereas the internalization of beta -ARs during late sepsis parallels the increased state of phosphorylation (Fig. 6), it is logical to conclude that a decrease in the receptor phosphorylation leads to the externalization of beta -ARs during early sepsis, whereas an increase in the receptor phosphorylation results in the internalization of beta -AR during late sepsis. These data offer an explanation on the molecular basis that the covalent modification of receptor proteins by phosphorylation/dephosphorylation is a mechanism responsible for the initial hyperexpression during early sepsis followed by a subsequent hypoexpression of beta -ARs during the late phase of sepsis.

Recent studies using transgenic mice overexpressing the beta -AR gene, beta -AR kinase (beta -ARK), or beta -ARK inhibitor provide additional evidence establishing the causal relationship between the expression of beta -ARs and myocardial function and role of receptor phosphorylation in the control of myocardial function. Milano et al. (16) and Rockman et al. (21) reported that transgenic mice overexpressing beta -AR gene had a 200-fold increase in beta -AR density, an increase in basal adenylate cyclase activity, and an enhanced myocardial function as evident by increases in left ventricle +dP/dtmax and -dP/dtmax (16, 21). In a separate report, Koch et al. (11) found that transgenic mice overexpressing beta -ARK-1 demonstrated attenuation of isoproterenol-stimulated left ventricle contractility in vivo, damping of myocardial adenylate cyclase activity, and reduced functional coupling of beta -ARs. Conversely, mice expressing beta -ARK inhibitor displayed enhanced cardiac contractility in vivo (11). These reports using transgenic animals illustrate a direct link regarding the cause-and-effect relationship between the increase in beta -AR density and the enhanced myocardial function and, furthermore, the important role of receptor phosphorylation/dephosphorylation in modulating in vivo myocardial function. Our findings of the hemodynamic changes (Table 3) associated with externalization or internalization of beta -ARs (Figs. 5 and 6) and the reduced or enhanced state of receptor phosphorylation (Figs. 2-4 and 6) in the early or late phase of sepsis are strikingly similar to those reported in transgenic mice overexpressing beta -AR gene, beta -ARK-1, or beta -ARK inhibitor (11, 16, 21). The similarities in the physiological and biochemical alterations between our studies using experimentally induced sepsis animals and those of transgenic mice overexpressing various genes strongly support the contention that 1) a decrease in the phosphorylation of receptors is a mechanism responsible for the externalization (overexpression) of beta -ARs, which, in turn, results in an enhanced myocardial contractility during the early hyperdynamic phase of sepsis and 2) an increase in the phosphorylation of receptors is a mechanism leading to internalization (underexpression) of beta -ARs, which, in turn results in a reduced myocardial contractility during the late hypodynamic phase of sepsis.

Perspectives

The findings presented in this study indicate that the externalization (overexpression) of beta -ARs in rat heart during the early hyperdynamic phase of sepsis is a result of the decreased phosphorylation of receptor proteins, whereas the internalization (underexpression) of beta -ARs during the late hypodynamic phase of sepsis is a consequence of the increased phosphorylation of receptors. Because protein phosphorylation and dephosphorylation can be regulated by various metabolic and pharmacological agents, our findings may have a therapeutic implication for the management of septic patients.

    ACKNOWLEDGEMENTS

The authors thank Dr. Suleiman W. Bahouth of The University of Tennessee, Memphis, for kindly providing beta 1-adrenergic receptor antiserum.

    FOOTNOTES

This work was supported by Grant HL-30080 from the National Heart, Lung, and Blood Institute and Grant GM-31664 from the National Institute of General Medical Science.

Address for reprint requests: M.-S. Liu, Dept. of Pharmacological and Physiological Science, Saint Louis Univ. Health Sciences Center, St. Louis, MO 63104-1083.

Received 8 November 1996; accepted in final form 7 January 1998.

    REFERENCES
Top
Abstract
Introduction
Methods
Results
Discussion
References

1.   Adams, H. Adenosine 5'-triphosphate determination with phosphoglycerate kinase. In: Methods of Enzymatic Analysis, edited by H. U. Bergmeyer. New York: Academic, 1963, p. 539-543.

2.   Bahouth, S. W., Y. Gokmen-Polar, E. C. Coronel, and J. N. Fain. Enhanced desensitization and phosphorylation of the beta 1-adrenergic receptor in rat adipocytes by peroxovanadate. Mol. Pharmacol. 49: 1049-1057, 1996[Abstract].

3.   Benovic, J. L., L. J. Pike, R. A. Cerione, C. Staniszewski, T. Yoshimasa, J. Codina, M. C. Caron, and R. J. Lefkowitz. Phosphorylation of the mammalian beta -adrenergic receptor by cyclic AMP-dependent protein kinase: regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory proteins. J. Biol. Chem. 260: 7094-7101, 1985[Abstract/Free Full Text].

4.   Bristow, M. R., R. Ginsbury, M. Minobe, R. S. Cubicciotti, W. S. Sageman, K. Lurie, M. E. Billingham, D. C. Harrison, and E. B. Stinson. Decreased catecholamine sensitivity and beta -adrenergic receptor density in failing human hearts. N. Engl. J. Med. 307: 205-211, 1982[Abstract].

5.   CoGoli, J. M., and J. G. Dobson, Jr. An easy and rapid method for the measurement of [gamma -32P]ATP specific radioactivity in tissue extracts obtained from in vitro rat heart preparations labeled with 32Pi. Anal. Biochem. 110: 331-337, 1981[Medline].

6.   Devos, C., P. Robberecht, P. Nokin, M. Waelbroeck, M. Clinet, J. C. Camus, P. Beaufort, P. Schoenfeld, and J. Christophe. Uncoupling between beta-adrenoceptors and adenylate cyclase in dog ischemic myocardium. Naunyn Schmiedebergs Arch. Pharmacol. 331: 71-75, 1985[Medline].

7.   Hansdorff, W. P., M. G. Caron, and R. J. Lefkowitz. Turning off the signal: desensitization of beta -adrenergic receptor function. FASEB J. 4: 2881-2889, 1990[Abstract].

8.   Jahns, R., C. Siegmund, V. Jahns, H. Reiländer, A. Maidhof, W. Müller-Esterl, M. J. Lohse, and F. Boege. Probing human beta 1- and beta 2-adrenoceptors with domain-specific fusion protein antibodies. Eur. J. Pharmacol. 316: 111-121, 1996[Medline].

9.   Karliner, J. S., P. Barnes, M. Brown, and C. Dollery. Chronic heart failure in the guinea pig increases cardiac alpha 1- and beta -adrenoceptors. Eur. J. Pharmacol. 67: 115-118, 1980[Medline].

10.   Kaufman, T. M., and J. W. Horton. Characterization of cardiac beta -adrenergic receptors in the guinea pig heart: application to study beta -adrenergic receptors in shock models. J. Surg. Res. 55: 516-523, 1993[Medline].

11.   Koch, W. J., H. A. Rockman, P. Samama, R. Hamilton, R. A. Bond, C. A. Milano, and R. J. Lefkowitz. Cardiac function in mice overexpressing the beta -adrenergic receptor kinase or a beta ARK inhibitor. Science 268: 1350-1353, 1995[Abstract/Free Full Text].

12.   Lefkowitz, R. J., and M. G. Caron. Regulation of receptor function by phosphorylation. J. Mol. Cell. Cardiol. 18: 885-895, 1986[Medline].

13.   Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951[Free Full Text].

14.   Maisel, A. S., H. J. Motulsky, and P. A. Insel. Life cycles of cardiac alpha - and beta -adrenergic receptors. Biochem. Pharmacol. 36: 1-6, 1987[Medline].

15.   Maisel, A. S., H. J. Motulsky, M. G. Ziegler, and P. A. Insel. Ischemia- and agonist-induced changes in alpha - and beta -adrenergic receptor traffic in guinea pig hearts. Am. J. Physiol. 253 (Heart Circ. Physiol. 22): H1159-H1165, 1987[Abstract/Free Full Text].

16.   Milano, C. A., L. F. Allen, H. A. Rockman, P. C. Dolber, T. R. McMinn, K. R. Chin, T. D. Johnson, R. A. Bond, and R. J. Lefkowitz. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 264: 582-586, 1994[Abstract/Free Full Text].

17.   Mukherjee, A., L. R. Bush, K. E. McCoy, R. J. Duke, H. Hagler, L. M. Buja, and J. T. Willerson. Relationship between beta -adrenergic receptor numbers and physiological responses during experimental canine myocardial ischemia. Circ. Res. 50: 735-741, 1982[Abstract/Free Full Text].

18.   Nelson, C. A., M. J. Katovich, and S. P. Baker. Beta-adrenergic responsiveness and cardiac autonomic receptors after implantation of the MtTW15 pituitary adenoma in the rat. Biochem. Pharmacol. 36: 1297-1302, 1987[Medline].

19.   Perkins, J. P., W. P. Hausdorff, and R. J. Lefkowitz. Mechanisms of ligand-induced desensitization of beta-adrenergic receptors. In: The Beta-Adrenergic Receptors, edited by J. P. Perkins. Clifton, NJ: Humana, 1991, p. 73-124.

20.   Rees, S., R. Pabla, M. K. Pugsley, K. Banner, and M. J. Curtis. Drugs and the cardiovascular system. In: Integrative Pharmacology, edited by C. P. Page, M. J. Curtis, M. C. Sutter, M. J. A. Walker, and B. B. Hoffman. St. Louis, MO: Mosby, 1997, p. 153-196.

21.   Rockman, H. A., R. Hamilton, L. R. Jones, C. A. Milano, L. Mao, and R. J. Lefkowitz. Enhanced myocardial relaxation in vivo in transgenic mice overexpressing the beta 2-adrenergic receptor is associated with reduced phospholamban protein. J. Clin. Invest. 97: 1618-1623, 1996[Medline].

22.   Sakagoshi, N., Y. Watanabe, H. Matsuda, Y. Kawashima, and H. Yoshida. Enhancement of beta -adrenoceptor function after reperfusion following cardioplegic arrest in rat hearts. J. Surg. Res. 51: 77-81, 1991[Medline].

23.   Scarpace, P. J., D. T. Lowenthal, and N. Tümer. Influence of exercise and age on myocardial beta -adrenergic receptor properties. Exp. Gerontol. 27: 169-177, 1992[Medline].

24.   Sibley, D. R., J. L. Benovic, M. G. Caron, and R. J. Lefkowitz. Regulation of transmembrane signaling by receptor phosphorylation. Cell 48: 913-922, 1987[Medline].

25.   Sibley, D. R., R. H. Strasser, J. L. Benovic, K. Daniel, and R. J. Lefkowitz. Phosphorylation/dephosphorylation of the beta -adrenergic receptor regulates its functional coupling to cyclase and subcellular distribution. Proc. Natl. Acad. Sci. USA 83: 9408-9412, 1986[Abstract/Free Full Text].

26.   Snavely, M. D., L. C. Mahan, D. T. O'Connor, and P. A. Insel. Selective down-regulation of adrenergic receptor subtype in tissues from rats with pheochromocytoma. Endocrinology 113: 354-361, 1983[Abstract].

27.   Stadel, J. M., and R. J. Lefkowitz. Beta-adrenergic receptors. In: The Beta-Adrenergic Receptors, edited by J. P. Perkins. Clifton, NJ: Humana, 1991, p. 1-40.

28.   Tang, C., and M. S. Liu. Initial externalization followed by internalization of beta -adrenergic receptors in rat heart during sepsis. Am. J. Physiol. 270 (Regulatory Integrative Comp. Physiol. 39): R254-R263, 1996[Abstract/Free Full Text].

29.   Tovey, K. C., K. G. Oldham, and J. A. M. Whelan. A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. Clin. Chim. Acta 56: 221-234, 1974[Medline].

30.   Tse, J., R. W. Wrenn, and J. F. Kuo. Thyroxine-induced changes in characteristics and activities of beta-adrenergic receptors and adenosine 3',5'-monophosphate systems in the heart may be related to reputed catecholamine supersensitivity in hyperthyroidism. Endocrinology 107: 6-16, 1980[Abstract].

31.   Wichterman, K. A., A. E. Baue, and I. H. Chaudry. Sepsis and septic shock: a review of laboratory models and a proposal. J. Surg. Res. 29: 189-201, 1980[Medline].


AJP Regul Integr Compar Physiol 274(4):R1078-R1086
0363-6119/98 $5.00 Copyright © 1998 the American Physiological Society



This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
N. FUJIMURA, S. SUMITA, E. NARIMATSU, Y. NAKAYAMA, Y. SHITINOHE, and A. NAMIKI
Effects of Isoproterenol on Diaphragmatic Contractility in Septic Peritonitis
Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 440 - 446.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, C.
Right arrow Articles by Liu, M.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, C.
Right arrow Articles by Liu, M.-S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online